For Doctors in a Hurry
- Clinicians lack data on whether nirmatrelvir-ritonavir prevents severe illness in vaccinated patients with SARS-CoV-2 infection.
- The researchers conducted two open-label trials involving 4232 higher-risk adults randomized to receive antiviral therapy or usual care.
- In the PANORAMIC trial, 0.8 percent of treated patients were hospitalized or died, compared to 0.7 percent in the control group.
- The authors concluded that nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated, higher-risk participants.
- These findings suggest that routine prescription of this antiviral may not provide clinical benefit for vaccinated, high-risk outpatients.
Reassessing Protease Inhibition in the Era of Hybrid Immunity
Since its introduction, nirmatrelvir-ritonavir has served as a primary outpatient therapy for patients at risk of progressing to severe COVID-19 [1, 2]. Early clinical data and target trial emulations established its efficacy in reducing hospitalization and mortality, particularly among unvaccinated individuals during the prevalence of earlier viral variants [3, 4]. However, the clinical landscape has shifted toward a population with high levels of hybrid immunity, which is the robust protection gained from a combination of vaccination and prior natural infection, alongside the dominance of less pathogenic variants [5]. While some meta-analyses continue to show benefits in specific high-risk groups, others suggest that the absolute risk reduction in the modern context may be narrowing [6, 7]. A new study now offers fresh insights into whether this antiviral remains effective for the contemporary vaccinated patient population.
While nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from SARS-CoV-2 in unvaccinated high-risk outpatients, its effectiveness in persons who have been vaccinated, infected naturally, or both is unclear. To address this clinical uncertainty, researchers utilized two open-label platform trials, which are flexible clinical trial designs that allow for multiple treatments to be tested simultaneously against a common control group while adapting to emerging data. These trials included PANORAMIC in the United Kingdom and CanTreatCOVID in Canada. Between December 8, 2021, and September 30, 2024, the researchers randomized a total of 3,516 participants in the PANORAMIC trial and 716 participants in the CanTreatCOVID trial to evaluate the impact of the antiviral therapy in a modern immunological context. The study enrolled higher-risk adults, a population defined as individuals at least 50 years of age or at least 18 years of age with coexisting conditions. All participants were treated in a community setting, had tested positive for SARS-CoV-2, and had been unwell for five days or less prior to randomization. This timeframe is critical for antiviral intervention, as protease inhibitors, which block the enzymes necessary for viral replication, are typically most effective during the early viral replication phase. Participants were randomly assigned to receive either usual care alone or usual care plus a five-day course of nirmatrelvir (300 mg) and ritonavir (100 mg) administered twice a day, the standard therapeutic dosage for this combination. The primary outcome for both trials was hospitalization or death from any cause within 28 days after randomization. This endpoint was selected to measure the drug's ability to prevent the most severe clinical deteriorations that require acute care or result in mortality. By focusing on these outcomes in a population with high levels of pre-existing immunity, the researchers sought to determine if the absolute risk reduction observed in earlier, unvaccinated cohorts still applies to the current vaccinated patient population seen in daily clinical practice.
Primary Outcomes and Statistical Probability of Superiority
The primary analysis of the PANORAMIC trial demonstrated that nirmatrelvir-ritonavir did not lower the risk of severe clinical progression in a highly vaccinated population. Among the participants randomized to the nirmatrelvir-ritonavir group, 14 of 1698 participants (0.8%) were hospitalized or died within 28 days, compared to 11 of 1673 participants (0.7%) in the usual-care group. The researchers calculated an adjusted odds ratio of 1.18, with a 95% Bayesian credible interval of 0.55 to 2.62. A Bayesian credible interval is a statistical range indicating where the true treatment effect is likely to fall based on the observed data and prior knowledge. These figures resulted in a probability of superiority of 0.334, meaning there was only a 33.4% chance that the antiviral intervention was more effective than usual care alone. For clinicians, these data suggest that in the context of contemporary immunity, the absolute risk of hospitalization is already low, and the addition of this protease inhibitor provides no further measurable protection. Results from the CanTreatCOVID trial in Canada mirrored this lack of clinical benefit, despite a slightly different distribution of events. In this cohort, 2 of 343 participants (0.6%) in the nirmatrelvir-ritonavir group were hospitalized or died, while 4 of 324 participants (1.2%) in the usual-care group reached the primary endpoint. The adjusted odds ratio for the primary outcome was 0.48, with a wide 95% Bayesian credible interval of 0.08 to 2.23. Although the probability of superiority for nirmatrelvir-ritonavir was higher at 0.830, it remained below the threshold required to establish a definitive clinical advantage. The wide credible intervals in both trials reflect the challenge of proving efficacy when baseline event rates are approximately 1% or lower, a significant shift from the high-risk, immunologically naive populations studied in earlier phases of the pandemic. The use of Bayesian statistics in these trials allowed the researchers to quantify the likelihood of treatment benefit rather than relying solely on traditional p-values. The probability of superiority represents the mathematical chance that the active treatment is better than the control based on the observed data. With values of 0.334 in PANORAMIC and 0.830 in CanTreatCOVID, the findings indicate that nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants. For the practicing physician, these results clarify that the routine prescription of nirmatrelvir-ritonavir for vaccinated outpatients may not yield the same reductions in severe outcomes observed in previous years, as the baseline risk in this population has been substantially mitigated by prior immunity.
Virological Response and Safety Profile
While the primary clinical endpoints were not met, the researchers conducted a secondary analysis to evaluate the biological activity of the protease inhibitor. In a substudy involving 634 participants, viral load was reduced by the end of treatment with nirmatrelvir-ritonavir, confirming that the medication maintained its expected mechanism of action by inhibiting viral replication. However, this virological response did not correlate with improved clinical outcomes in the study population. For the practicing clinician, this discrepancy suggests that while the drug effectively lowers the amount of SARS-CoV-2 present in the upper respiratory tract, this reduction does not translate into a further decrease in the already low rates of severe disease seen in patients with pre-existing immunity. Safety data from both platform trials indicated that the treatment was generally well tolerated, though serious complications were documented. Serious adverse events with nirmatrelvir-ritonavir were reported in 9 participants in the PANORAMIC trial and in 4 participants in the CanTreatCOVID trial. These events represent a small fraction of the thousands of patients randomized, yet they must be weighed against the lack of demonstrated efficacy in this specific cohort. Because the baseline risk of progression is minimal in vaccinated individuals, the risk-to-benefit ratio for prescribing this antiviral combination has shifted significantly since its initial authorization. The synthesis of these findings across two large, open-label trials provides a clear directive for outpatient management. Despite the observed reduction in viral titers, nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. These results indicate that for patients who have already achieved a level of protection through vaccination or natural infection, the routine addition of nirmatrelvir-ritonavir provides no significant clinical advantage in preventing the most severe manifestations of the disease.
References
1. Hammond J, Leister-Tebbe H, Gardner A, et al. Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. doi:10.1093/cid/ciae551
2. Denning K, Sheppard J, Carico R. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.. Journal of the American Pharmacists Association : JAPhA. 2024. doi:10.1016/j.japh.2023.12.017
3. Yan L, Bui D, Li Y, et al. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024. doi:10.1093/cid/ciae202
4. Huang C, Kuo S, Lin L. Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis. 2024. doi:10.4103/etmj.etmj-d-24-00005
5. Haslam A, Prasad V. A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019.. Open forum infectious diseases. 2024. doi:10.1093/ofid/ofae497
6. Ibrahim S, Siemieniuk RAC, Oliveros MJ, et al. Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.. BMJ (Clinical research ed.). 2025. doi:10.1136/bmj-2024-081165
7. Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.. Journal of medical virology. 2023. doi:10.1002/jmv.28889
